Bio-Rad Recalls Liquichek ToRCH Plus IgM Control Due to HCV RNA
Bio-Rad is recalling Liquichek ToRCH Plus IgM Control - Positive because it contains detectable levels of HCV RNA originating from the manufacturing process.
The agency’s classification
FDA (Devices): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences. The presence of HCV RNA in a quality control serum represents a contamination issue, but the product is not intended for direct patient use or blood donor screening, limiting the immediate risk.
Plain-English summary
Bio-Rad Laboratories, Inc. is recalling the Liquichek ToRCH Plus IgM Control - Positive product. This product is an unassayed quality control serum intended to monitor the precision of IgM laboratory testing procedures for specific analytes, including Cytomegalovirus, Herpes Simplex Virus, Rubella Virus, and Toxoplasma gondii. The product is not intended for use in blood donor screening assays.
The recall is being issued because the product contains detectable levels of Hepatitis C Virus (HCV) RNA. According to the source text, this HCV RNA originated from the non-specific human IgM component used in the mouse monoclonal antibody conjugation process for this product.
The affected units include 211 boxes and 5 MiniPaks of Lot Number 18972, Catalog Number 229 and 229PX. The product was distributed worldwide, specifically in San Juan, Puerto Rico, and the states of New Mexico, New York, Minnesota, Oregon, and Wisconsin, as well as in Australia, Brazil, France, Italy, Korea, and New Zealand. Users should stop using the affected product and contact Bio-Rad Laboratories for further instructions.
The recalled product
- Product
- Liquichek" ToRCH Plus IgM Control - Positive Liquichek ToRCH Plus IgM Control is intended for use as an unassayed quality control serum to monitor precision of IgM laboratory testing procedures for the analytes listed in this package insert. This product is not intended for…
- Manufacturer
- Bio-rad Laboratories, Inc.
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot Number 18972
- Catalog Number 229 and 229PX.
Distribution
Related recalls
Same manufacturer · Bio-rad Laboratories, Inc.
See all →- HighToxoplasma IgM assay kits recalled over risk of false positive results
FDA (Devices) · 2025-09-10
- HighAPLS IgM Diagnostic Reagent Packs Recalled Due to Incorrect Conjugate
FDA (Devices) · 2023-05-17
- HighBioPlex 2200 Anti-CCP Reagent Kit recalled due to reduced test specificity
FDA (Devices) · 2023-04-19
- HighBioPlex 2200 Anti-CCP Reagent Pack Recalled for Reduced Diagnostic Specificity
FDA (Devices) · 2023-04-19
- HighCMV IgM EIA Diagnostic Test Recalled for Increased False Positives
FDA (Devices) · 2022-12-07
Similar recalls
- HighPositive control serum recalled over negative recovery of the HBsAg analyte
FDA (Devices) · 2025-11-19
- ModerateSerology ToRCH positive control specimen recalled for decreased HSV reactivity
FDA (Devices) · 2024-01-10
- HighSecond control serum lot recalled over negative HBsAg analyte recovery
FDA (Devices) · 2025-11-19
- HighCMV IgM EIA Diagnostic Test Recalled for Increased False Positives
FDA (Devices) · 2022-12-07
- HighBioPlex 2200 CMV IgM Reagent Pack Recalled for Variable Test Performance
FDA (Devices) · 2022-05-25
- ModerateSiemens Healthcare Recalls TSH Calibrator Vials Due to Dose Recovery Issues
FDA (Devices) · 2013-01-16